Q-omics provides the consensus-scored CYTH3 profile across patient tissues and cancer cell-line models. CYTH3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CYTH3 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, CYTH3 protein abundance shows 36,722 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where CYTH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYTH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYTH3 survival associations across molecular data types. CYTH3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYTH3 RNA expression–survival associations across cancer types. High CYTH3 expression shows unfavorable associations in BLCA, ACC, KICH, UVM and COAD, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CYTH3 RNA expression.
This table summarizes CYTH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CYTH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYTH3 shows lower tumor expression in THCA, UCEC and BRCA and higher tumor expression in HNSC, LIHC and CHOL. The THCA box plot shows higher CYTH3 RNA expression in normal versus tumor tissue (log2 FC = −1.771, t-test p < 0.001).
This table shows molecular features associated with CYTH3 in patient tissues and cancer cell lines. In patient samples, CYTH3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYTH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
